In 2018, Turkan et al. reported a series of substituted pyrazol-4-yl-diazene derivatives (3), and their in vitro enzymatic assay suggested that all were effective AChE and BuChE inhibitors with Ki values at the nanomole level, better than tacrine (164), a discontinued acetylcholinesterase inhibitor that was used to treat AD [7]. This evidence concerns the gene ACHE and Alzheimer disease.